Rolf Bruns

1.9k total citations
64 papers, 510 citations indexed

About

Rolf Bruns is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Rolf Bruns has authored 64 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 8 papers in Hepatology. Recurrent topics in Rolf Bruns's work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Lung Cancer Research Studies (23 papers). Rolf Bruns is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Lung Cancer Research Studies (23 papers). Rolf Bruns collaborates with scholars based in Germany, United States and Japan. Rolf Bruns's co-authors include Paul K. Paik, Josef Straub, Andreas Johne, J. Sträub, Maha Hussain, Kurt Miller, J. Scheele, Enriqueta Felip, Sylvestre Le Moulec and Claude Gimmi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Rolf Bruns

64 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rolf Bruns Germany	10	304	257	152	121	88	64	510
Mitsutoshi Tatsumi Japan	9	394 1.3×	337 1.3×	270 1.8×	132 1.1×	93 1.1×	25	756
Nerissa Mendoza United States	8	245 0.8×	229 0.9×	335 2.2×	217 1.8×	95 1.1×	10	620
Masahiko Matsuda Japan	7	256 0.8×	356 1.4×	290 1.9×	132 1.1×	100 1.1×	13	664
P.N. Munster United States	12	119 0.4×	336 1.3×	307 2.0×	31 0.3×	72 0.8×	18	584
Nobuteru Kikkawa Japan	14	164 0.5×	404 1.6×	369 2.4×	81 0.7×	165 1.9×	71	811
Marco Imperatori Italy	10	121 0.4×	273 1.1×	111 0.7×	62 0.5×	75 0.9×	13	424
Rebecca Pharaon United States	10	166 0.5×	210 0.8×	181 1.2×	16 0.1×	32 0.4×	27	408
Silvana Vignati Italy	7	218 0.7×	184 0.7×	257 1.7×	53 0.4×	29 0.3×	9	489
Meghan Nechrebecki United States	3	238 0.8×	404 1.6×	226 1.5×	26 0.2×	37 0.4×	4	542
Margarita Donica Switzerland	11	285 0.9×	438 1.7×	105 0.7×	45 0.4×	58 0.7×	19	632

Countries citing papers authored by Rolf Bruns

Since Specialization

Citations

This map shows the geographic impact of Rolf Bruns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rolf Bruns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rolf Bruns more than expected).

Fields of papers citing papers by Rolf Bruns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rolf Bruns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rolf Bruns. The network helps show where Rolf Bruns may publish in the future.

Co-authorship network of co-authors of Rolf Bruns

This figure shows the co-authorship network connecting the top 25 collaborators of Rolf Bruns. A scholar is included among the top collaborators of Rolf Bruns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rolf Bruns. Rolf Bruns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rolfo, Christian, Aurora O’Brate, Rolf Bruns, et al.. (2025). Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib. Clinical Cancer Research. 31(13). 2675–2684. 1 indexed citations

Amato, Federico, Rainer Strotmann, Roberto Castello, et al.. (2024). Explainable machine learning prediction of edema adverse events in patients treated with tepotinib. Clinical and Translational Science. 17(9). e70010–e70010. 2 indexed citations

Viteri, Santiago, Enriqueta Felip, Frank Griesinger, et al.. (2023). 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial. Annals of Oncology. 34. S791–S792. 3 indexed citations

Liam, Chong Kin, Te‐Chun Hsia, Jianying Zhou, et al.. (2023). Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research. 29(10). 1879–1886. 22 indexed citations

Rolfo, Christian, C Menzel, Rolf Bruns, et al.. (2023). 1382P Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib. Annals of Oncology. 34. S793–S793. 3 indexed citations

Griesinger, Frank, Egbert F. Smit, Rémi Veillon, et al.. (2022). 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy. Annals of Oncology. 33. S40–S41. 2 indexed citations

Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2022). O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION). Annals of Oncology. 33. S475–S475. 1 indexed citations

Yang, James Chih‐Hsin, M-J. Ahn, Hiroya Sakai, et al.. (2022). 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. Annals of Oncology. 33. S41–S42. 1 indexed citations

Kato, Terufumi, James Chih‐Hsin Yang, Myung‐Ju Ahn, et al.. (2022). Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.. Journal of Clinical Oncology. 40(16_suppl). 9120–9120. 1 indexed citations

10.

Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2021). OA05.03 Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A. Journal of Thoracic Oncology. 16(1). S5–S5. 1 indexed citations

11.

Decaens, Thomas, Carlo Barone, Eric Assénat, et al.. (2021). Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(3). 465–465. 2 indexed citations

12.

Viteri, Santiago, Julien Mazières, Rémi Veillon, et al.. (2020). 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 31. S831–S831. 6 indexed citations

13.

Mazières, Julien, Paul K. Paik, Enriqueta Felip, et al.. (2020). 1283P Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A. Annals of Oncology. 31. S828–S829. 4 indexed citations

14.

Falchook, Gerald S., Razelle Kurzrock, Hesham M. Amin, et al.. (2019). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1237–1246. 67 indexed citations

15.

Wu, Yi‐Long, Ying Cheng, Jianfeng Zhou, et al.. (2019). MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up. Journal of Thoracic Oncology. 14(10). S284–S284. 7 indexed citations

16.

Wu, Yi‐Long, Jianya Zhou, Shun Lü, et al.. (2018). Tepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data. Annals of Oncology. 29. ix159–ix159. 2 indexed citations

17.

Paik, Paul K., Hiroshi Sakai, Rolf Bruns, et al.. (2018). Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress. Annals of Oncology. 29. ix169–ix169. 3 indexed citations

18.

Hussain, Maha, Sylvestre Le Moulec, Claude Gimmi, et al.. (2016). Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(13). 3192–3200. 48 indexed citations

19.

Paik, Paul K., Uz Stammberger, & Rolf Bruns. (2016). A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy. Annals of Oncology. 27. vi450–vi450. 1 indexed citations

20.

Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Annals of Oncology. 26(1). 132–140. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact